 |
|
|
| |
Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naïve Patients: 192 Week Results from STARTMRK
|
| |
| |
Reported by Jules Levin
IDSA 49th Annual Meeting
October 20-23, 2011Boston, MA
E. DeJesus1, J. Rockstroh2, J. Lennox3, M. Saag4, A. Lazzarin5, H. Wan6, A. RODGERS6, K. STROHMAIER6, H. TEPPLER6, B-Y. NGUYEN6, R. LEAVITT6, P. SKLAR and the STARTMRK Study Team
1Orlando Immunology Center, Orlando, FL; 2University of Bonn, Bonn, Germany; 3Emory University School of Medicine, Atlanta, GA; 4University of Alabama at Birmingham, Birmingham, AL; 5Universita Vita-Salute San Raffaele, Milan, Italy; 6Merck, Whitehouse Station, NJ
|
| |
|
|
|
|
|
